Found 4366 articles for: ""
The Patient-Physician Relationship and Adherence: Observations From a Clinical Study
August 2023 | Volume 22 | Issue 8 | Editorials | 838 | Copyright © August 2023
Improved patient-physician relationships (PPR) are associated with better patient satisfaction and disease outcomes, however, there is limited literature assessing how PPR affects adherence in de...
Read MoreAntimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study
August 2023 | Volume 22 | Issue 8 | Editorials | 840 | Copyright © August 2023
The early phase of the COVID-19 pandemic prompted a repurposing of antiviral and immunomodulatory drugs as investigational therapeutics, including hydroxychloroquine and chloroquine. While antima...
Read MoreRethinking the Inflammatory Balance in Psoriasis and Atherosclerosis
August 2023 | Volume 22 | Issue 8 | Features | 832 | Copyright © August 2023
Guénin S, Kazemi A, Cline A, et al. Rethinking the inflammatory balance in psoriasis and atherosclerosis. J Drugs Dermatol. 2023;22(8):832-833. doi:10.36849/JDD.7082...
Read MoreA Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults
August 2023 | Volume 22 | Issue 8 | Original Article | 761 | Copyright © August 2023
Psoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque ...
Read MoreReal-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study
August 2023 | Volume 22 | Issue 8 | Original Article | 754 | Copyright © August 2023
Background: Tildrakizumab is an anti–interleukin-23 p19 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis. This analysis eva...
Read MoreReview of Superficial Cryotherapy for the Treatment of Alopecia Areata
August 2023 | Volume 22 | Issue 8 | Original Article | 802 | Copyright © August 2023
Cryotherapy has recently been examined as a potential treatment for alopecia areata (AA). AA is classically managed with intralesional or systemic steroids but relapse rates among those with long...
Read MoreHormonal Treatments in Hidradenitis Suppurativa: A Systematic Review
August 2023 | Volume 22 | Issue 8 | Original Article | 785 | Copyright © August 2023
Background: Hidradenitis suppurativa (HS) is an inflammatory skin condition characterized by recurrent abscesses, nodules, and sinus tracts. Hormones are thought to play an impor...
Read MoreTapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 779 | Copyright © August 2023
Topical treatments remain the foundation of psoriasis management. Tapinarof (VTAMA®; Dermavant Sciences, Inc.) is a first-in-class, non-steroidal, topical, aryl hydrocarbon receptor (AhR) ago...
Read MoreJuvenile Pemphigus Foliaceus in a Patient With Psoriasis Receiving Narrow-Band Ultraviolet-B: Successful Treatment With Rituximab
August 2023 | Volume 22 | Issue 8 | Case Reports | 830 | Copyright © August 2023
Pemphigus foliaceus is an autoimmune blistering disease of the skin that is not frequently associated with mucous membrane involvement. It is characterized by immunoglobulin G (IgG) antibodies ag...
Read MoreTalquetamab-Induced Grover's Disease
August 2023 | Volume 22 | Issue 8 | Case Reports | 828 | Copyright © August 2023
Kresch M, Guénin S, Mubasher A, et al. Talquetamab-induced Grover’s disease. J Drugs Dermatol. 2023;22(8):828-829. doi:10.36849/JDD.7170...
Read MoreVerrucous Psoriasis: Rare Variant and Novel Treatment
August 2023 | Volume 22 | Issue 8 | Case Reports | 826 | Copyright © August 2023
Xenopoulou D, Pochat C, Greco E. Verrucous psoriasis: rare variant and novel treatment. J Drugs Dermatol. 2023;22(8):826-827. doi:10.36849/JDD.C6874R1...
Read MoreRacial Disparities in the Treatment of Hidradenitis Suppurativa: An Analysis of Data from the National Ambulatory Medical Care Survey
July 2023 | Volume 22 | Issue 7 | Features | 692 | Copyright © July 2023
Hidradenitis suppurativa (HS) is a painful, disfiguring, chronic inflammatory disease affecting the axillary, inframammary, and groin regions. Black Americans are disproportionately affected by H...
Read MoreLeukemia Cutis in Skin of Color
July 2023 | Volume 22 | Issue 7 | Case Reports | 687 | Copyright © July 2023
The various presentations of many dermatologic conditions among various skin types are slowly being elucidated throughout the recent years. These differences present as an issue as it leads to de...
Read MoreNitric Oxide as a Promising Antiviral Agent: What Dermatologists Should kNOw
July 2023 | Volume 22 | Issue 7 | Features | 719 | Copyright © July 2023
Diagnosis of Skin Disease in Moderately to Highly Pigmented Skin by Artificial Intelligence
July 2023 | Volume 22 | Issue 7 | Original Article | 647 | Copyright © July 2023
Background: Triage of patients with skin diseases often includes an initial assessment by a nurse or general practitioner, followed by a dermatologist. Artificial intelligence (A...
Read MoreEfficacy, Convenience, and Safety of Calcipotriene-Betamethasone Dipropionate Cream in Skin of Color Patients With Plaque Psoriasis
July 2023 | Volume 22 | Issue 7 | Original Article | 668 | Copyright © July 2023
Background: Psoriasis affects diverse racial and ethnic groups. In July 2021, the US Food and Drug Administration approved calcipotriene/betamethasone dipropionate (CAL/BDP) 0.00...
Read MoreWATCH VIDEO ABSTRACT: Assessing Implicit Bias in Dermatology
July 2023 | Volume 22 | Issue 7 | Original Article | 635 | Copyright © July 2023
Read MoreRacial and Ethnic Variations in Skin Barrier Properties and Cultural Practices in Skin of Color Newborns, Infants, and Children
July 2023 | Volume 22 | Issue 7 | Original Article | 657 | Copyright © July 2023
Background: The skin of newborns and infants of all races/ethnicity is more susceptible to skin barrier disruption than adult skin. This consensus paper offers insights into pote...
Read MoreA Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo
July 2023 | Volume 22 | Issue 7 | Original Article | 664 | Copyright © July 2023
Background: This article describes the clinical trial, safety, and efficacy of ruxolitinib 1.5% cream or repigmentation in patients with vitiligo.Data Sources: A sys...
Read MoreSkin of Color Sun Protection: Reddit Analysis Reveals Perceptions, Preferences, Unmet Needs, and Knowledge Gaps
July 2023 | Volume 22 | Issue 7 | Original Article | 673 | Copyright © July 2023
Media and other results for: ""